Literature DB >> 12173814

Proinflammatory and antiinflammatory cytokines after cardiac operation: different cellular sources at different times.

Axel Franke1, Wolfgang Lante, Volker Fackeldey, Horst Peter Becker, Christian Thode, Wolf Dieter Kuhlmann, Andreas Markewitz.   

Abstract

BACKGROUND: Cardiac operation produces substantial alterations within the immune system, which possibly predispose postoperative complications. However, the interplay between proinflammatory and antiinflammatory reactions and the cells involved in this process are not completely clear. Therefore, we investigated serum levels, as well as synthesis patterns, of proinflammatory and antiinflammatory cytokines.
METHODS: Serum levels and production of interleukin (IL) IL-5, IL-6, IL-10, tumor necrosis factor-alpha, and interferon-gamma, using a mixed cell culture, (ie, monocytes, macrophages, and lymphocytes), as well as a purified lymphocyte culture were measured preoperatively (day 0), on postoperative day 1, on postoperative day 3, and on postoperative day 5 in 25 patients undergoing cardiac operations and were compared with 10 healthy volunteers.
RESULTS: Serum level and mixed cell culture, production of IL-6, tumor necrosis factor-alpha, and IL-10 increased on postoperative day 1, but decreased in lymphocyte culture. Base line values were reached on postoperative day 5. Interferon-gamma serum levels remained unchanged, whereas IL-5 serum levels increased on postoperative days 3 and 5. Cell culture synthesis showed a significant suppression for both mediators in both cell cultures, which returned to baseline on postoperative day 3 in mixed cell culture. Interferon-gamma production by lymphocytes was suppressed until postoperative day 5, whereas IL-5 returned to preoperative values on postoperative day 5.
CONCLUSIONS: Cardiac operation induces a biphasic immune response. The first phase (postoperative day 1) appears to represent the proinflammatory and antiinflammatory reaction of the innate immune system returning to base line on postoperative day 3. The second phase (postoperative day 5) may represent the response of the adaptive immune system and is characterized by an antiinflammatory type of reaction. This may explain why the systemic inflammatory response occurs immediately after cardiac operation, whereas infections occur later.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12173814     DOI: 10.1016/s0003-4975(02)03658-5

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  12 in total

1.  Chemical mediators of inflammation and resolution in post-operative abdominal aortic aneurysm patients.

Authors:  Padmini S Pillai; Stanley Leeson; Timothy F Porter; Christopher D Owens; Ji Min Kim; Michael S Conte; Charles N Serhan; Simon Gelman
Journal:  Inflammation       Date:  2012-02       Impact factor: 4.092

2.  Investigating the Impacts of Preoperative Steroid Treatment on Tumor Necrosis Factor-Alpha and Duration of Extubation Time underwent Ventricular Septal Defect Surgery.

Authors:  H Hakan Poyrazoğlu; Zeynel Duman; Şerafettin Demir; M Kemal Avşar; Atakan Atalay; Bahattin Çiftçi; İhsan Bayraktar; Funda Tor
Journal:  Balkan Med J       Date:  2016-03-01       Impact factor: 2.021

3.  The Effect of Pressure-Controlled Ventilation and Volume-Controlled Ventilation in Prone Position on Pulmonary Mechanics and Inflammatory Markers.

Authors:  Hasan Şenay; Remziye Sıvacı; Serdar Kokulu; Buğra Koca; Elif Doğan Bakı; Yüksel Ela
Journal:  Inflammation       Date:  2016-08       Impact factor: 4.092

4.  Preoperative statins improve recovery of renal function but not by an anti-inflammatory effect: observational study in 69 elderly patients undergoing cardiac surgery.

Authors:  Pierangela Presta; Antonino S Rubino; Gaetano Lucisano; Giuseppe F Serraino; Daniela Foti; Elio Gulletta; Attilio Renzulli; Giorgio Fuiano
Journal:  Int Urol Nephrol       Date:  2011-04-20       Impact factor: 2.370

5.  Effects of 60 minutes of hyperoxia followed by normoxia before coronary artery bypass grafting on the inflammatory response profile and myocardial injury.

Authors:  Inga Karu; Peeter Tähepõld; Arno Ruusalepp; Kersti Zilmer; Mihkel Zilmer; Joel Starkopf
Journal:  J Negat Results Biomed       Date:  2012-09-14

6.  STAT3 regulates monocyte TNF-alpha production in systemic inflammation caused by cardiac surgery with cardiopulmonary bypass.

Authors:  Petrus R de Jong; Alvin W L Schadenberg; Theo van den Broek; Jeffrey M Beekman; Femke van Wijk; Paul J Coffer; Berent J Prakken; Nicolaas J G Jansen
Journal:  PLoS One       Date:  2012-04-10       Impact factor: 3.240

7.  Hemoglobin-associated oxidative stress in the pericardial compartment of postoperative cardiac surgery patients.

Authors:  Philip A Kramer; Balu K Chacko; Saranya Ravi; Michelle S Johnson; Tanecia Mitchell; Stephen Barnes; Alireza Arabshahi; Louis J Dell'Italia; David J George; Chad Steele; James F George; Victor M Darley-Usmar; Spencer J Melby
Journal:  Lab Invest       Date:  2014-12-01       Impact factor: 5.662

8.  Effect of hemoadsorption during cardiopulmonary bypass surgery - a blinded, randomized, controlled pilot study using a novel adsorbent.

Authors:  Martin H Bernardi; Harald Rinoesl; Klaus Dragosits; Robin Ristl; Friedrich Hoffelner; Philipp Opfermann; Christian Lamm; Falk Preißing; Dominik Wiedemann; Michael J Hiesmayr; Andreas Spittler
Journal:  Crit Care       Date:  2016-04-09       Impact factor: 9.097

9.  Hemoperfusion with HA380 in acute type A aortic dissection patients undergoing aortic arch operation (HPAO): a randomized, controlled, double-blind clinical trial.

Authors:  Jing Yang; Dong Ji; Yue-Qian Zhu; Yun Ren; Xun Zhang; Hong-Yu Dai; Xu Sun; Yi Zhou; Zhi-Yuan Chen; Qing-Guo Li; Hao Yao
Journal:  Trials       Date:  2020-11-23       Impact factor: 2.279

10.  RECCAS - REmoval of Cytokines during CArdiac Surgery: study protocol for a randomised controlled trial.

Authors:  Andreas Baumann; Dirk Buchwald; Thorsten Annecke; Martin Hellmich; Peter K Zahn; Andreas Hohn
Journal:  Trials       Date:  2016-03-12       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.